Fig. 7: SAR131675 decreases high-glucose and palmitate-induced vascular endothelial cell growth factor-C (VEGF-C), vascular endothelial cell growth factor receptor-3 (VEGFR-3), and LYVE-1 expression and M polarization in RAW264.7 cells. | Cell Death & Disease

Fig. 7: SAR131675 decreases high-glucose and palmitate-induced vascular endothelial cell growth factor-C (VEGF-C), vascular endothelial cell growth factor receptor-3 (VEGFR-3), and LYVE-1 expression and M polarization in RAW264.7 cells.

From: Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice

Fig. 7Fig. 7

To determine whether SAR131675 might modulate lymphangiogenesis and macrophage polarization in RAW264.7 murine macrophage cells, the cells were stimulated with palmitate (500 μM) in high-glucose medium (HG; 30 mmol/l d-glucose) and exposed to SAR131675 at 1, 10, and 100 nM. a Representative western blots for VEGF-C, VEGFR-1, VEGFR-2, VEGFR-3, and β-actin and quantitative data. b Representative western blots for CD68, arginase I, and arginase II, inducible nitric oxide synthase (iNOS), and β-actin and quantitative data. c Representative confocal microscopy images showing dihydroethidium (DHE) and MitoSOX fluorescence in the human kidney-2 (HK2) and RAW264.7 cells and quantitative data. *P < 0.05, **P < 0.01, #P < 0.001 vs. control

Back to article page